Patent EA-001339-B1 (EA)
Title: Antimicrobial treatment for herpes simplex virus and other infectious diseases
IPC: A61K38/28
Filed: 1997-03-12
Abstract: 1. A medical composition comprising a plant and a surfactant, characterized in that the plant is Echinacea, and the surfactant is benzalkonium halide. 2. A medical composition according to claim 1, characterized in that comprising by weight: from about 2% to about 90% of an Echinacea plant; benzalkonium halide from about 0.005% to about 0.8%. 3. A medical composition according to any preceding claim, characterized in that a diluent and carrier for the composition is water. 4. A medical composition according to any preceding claim, characterized in that comprising by weight: from about 40% to about 60% of an Echinacea plant; and  benzalkonium halide from about 0.002% to about 0.30%; water from about 30% to about 60%. 5. A medical composition according to any preceding claim, characterized in that the benzalkonium halide is a benzalkonium chloride. 6. A medical composition according to any preceding claim, characterized in that the Echinacea plant is selected from the group consisting of Echinacea purpurea, Echinacea angustifolia, Echinacea pallidae, Echinacea vegetalis or Echinacea atribactilus. 7. A medical composition according to any preceding claim, characterized in that the Echinacea plant is Echinacea purpurea or Echinacea angustifolia. 8. A medical composition according to any preceding claim, characterized in that the Echinacea plant comprises phytochemicals selected from the group consisting of: echinacen; echinacen B; echinaceine; echinacoside; caffeic acid ester; echinolone; enzymes; glucuronic acid; inulini; inuloid; pentadecadiene; polyacelylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O- methylglucoronoarabinoxylan, Mr = 35Kd); PSII (an acid rhamnoarbinogalactan, Mr = 450 kD); cynarin; 1, 5-di-O-caffeoylquinic acid; acid; 2, 3-O-dicaffeoyltartaric acid; borneol; bornyl acetate; pentadeca 8 (z) - en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-O-β-D-glucopyranoside; 3-O-(6-O-malonyl-β-D-glucopyranoside; tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoic acid; or carophylenes. 9. A medical composition according to any preceding claim, characterized in that the Echinacea plant comprises phytochemicals by weight based upon the total weight of the medical composition: from about 0.3% to about 9% echinacoside; from about 0.15% to about 7% PSI (4-O methylglucoronoarabinoxylan, Mr = 35 kD) and PSII (acid rhamnoarabinogalactan, Mr = 450 kD); from about 0.1% to about 10% cynarin (1, 5-di-O caffeoylquinic acid) and acid (2, 3-O-di-caffeoyltartaric acid) and derivatives thereof; from about 0.2% to about 4% echinolone; from about 0.2% to about 8% echinacin B; from about 0.1% to about 6% echinaceine;  from about 2% to about 7% anthonocyanins comprising cynanidin 3-O-β-D-glucopyranoside and 3-O-(6-O-malonyl)-β-D-glucopyranoside; from about 0.01% to about 0.06% pyrrolizidine alkaloids comprising tussilagine and isotussilagine; from about 0.003% to about 0.009% isomeric dodeca isobutyalamides and tetroenoic acid; and from about 0.01% to about 2% caryophylenes. 10. Use of the medical composition according to any preceding claim for preparing a formulation for treating a disease, characterized in that an agent of this disease belongs to the group consisting of: herpes simplex virus 1, herpes simplex virus 2, varicella zoster virus (herpes zoster), cytomegalovirus, human immunodeficiency virus or Epstein Barr virus. 11. A method for use in treating herpes virus or other infectious diseases, comprising the steps of: topically applicating an effective amount of the antimicrobal compound to an infected area of said herpes simplex virus or said other infectious microbial disease and maintaining said antimicrobial compound on said infected area for a predetermined time, characterized in that said antimicrobial compound comprises by weight: from about 2% to about 90% of a phytochemical concentrate of Echinacea, comprising at least one plant selected from the group consisting of Echinacea purpurea, Echinacea angustifolia, Echinacea pallidae, Echinacea vegetalis or Echinacea atribactilus; and  said phytochemical concentrate comprising antimicrobial isolates selected from the group consisting antimicrobial isolates selected from the group consisting of: echinacen; echinacen B; echinaceine; echinacoside; caffeic acid ester; echinolone; enzymes; glucuronic acid; inulin; inuloid; pentadecadiene; polyacelylene compounds; polysaccharides; arabinogalactan; rhamnose; tannins; PSI (a 4-O-methylglucoronoarabinoxylan, Mr = 35 Kd); PSII (an acid rhamnoarbinogalactain, Mr = 450 kD); cynarin; 1, 5-di-O-caffeoylquinic acid; chicoric acid; 2, 3-O di-caffeoyltartaric acid; borneol; borneol acetate; pentadeca - 8 (z) - en-zone; germacrene D; caryophyllene; caryophyllene epoxide; anthocyanin, pyrolizidine alkaloid, lipophilic amide; isobutylamide; polyacetylene; anthocyanin; 3-O-β-D-glucopyranoside; 3-O-(6-O-malonyl)- β-D-glucopyranoside; tussilagine; isotussilagine; isomeric dodeca isobutylamide; tetraenoic acid; or carophylenes; from about 0.005% to about 0.8% quaternary ammonium salt surfactant comprising a member selected from the group consisting of alkyl dimethylbenzylammonium chloride, benzalkonium halide, benzalkonium bromide, benzathonium chloride, alkylbenzyldimethylammonium chloride, alkyldimethybethylbenzylammonium chloride, alkyldimethylbenzylammonium chloride, diisobutylphenoxyethoxethyl dimethylammonium chloride, ndimethylbenzylammonium chloride, octyldecyldimethylammonium chloride, didecyldimethylammonium chloride, dioctyldimethylammonium chloride, diakyldimethylammonium chloride, octyldecylidimethylammonium chloride, laurryl dimethylbenzylammonium chloride, o-benzyl -p- chlorophenol, dideryldimethylammonium chloride, doctyldimethylammonium chloride, alkyldimethylbenzylammonium chloride, and alkylbenzyldimethylammonium chloride; and sterile water providing a diluent and carrier for said phytochemical concentrate, and the overall ratio of said sterile water to said phytochemical concentrate and said ammonium salt surfactant ranges from about 2:1 to about 100:1 and maintaining said antimicrobial compound on said infected area for about 1 hours to about 30 hours. 12. A method according to claim 11, characterized in that said infected area is rinsed and dried to remove any soap or residue on the infected area before said antimicrobial compound is applied; and said ammonium salt surfactant comprises benzalkonium chloride and the surfactant ratio of said sterile water to said benzalkonium chloride ranges from about 30,000:1 to about 250:1. 13. A method according to any of claims 11 and 12, characterized in that said applying is selected from the group consisting of spraying, dabbing, dusting, swabbing, sponging, brushing, pouring, dispensing, covering and coating; and said infected area is selected from the group consisting of oral mucosa, nasal mucosa, vaginal tissue, penile tissue, labial tissue, anal tissue, periacinal tissue, lips, cutaneous tissue, sub-cutaneous tissue, ocular tissue, conjunctive and eyelids. 14. A method according to any of claims 11 to 13, characterized in that vesicular eruption of said herpes simplex virus are resolved in about 19 hours to about 24 hours by maintaining said antimicrobial compound on said infected area for about 19 hours to about 24 hours; said herpes simplex virus comprising herpes simplex virus 1 or herpes simplex virus 2; and said antimicrobial compound comprises by weight: from about 40% to about 60% of said phytochemical concentrate;  from about 0.02% to about 0.30% ammonium salt surfactant comprising benzalkonium chloride; and from about 20% to about 60% sterile water. 15. A method according to any of claims 11 to 14, characterized in that controlling viral shedding, or healing lesions and extending the latency period of said herpes virus simplexis carried out by applicating to an infected area of said selected antimicrobial compounds of phytochemical concentrate by weight based upon the total weight of the antimicrobial compound: from about 0.3% to about 9% echinacoside; from about 0.1% to about 7% PSI (4-O-methylglucoronoarabinoxylan, Mr = 35 kD) and PSII (acid rhamnoarabinogalactan, Mr = 450 kD); from about 0.1% to about 10% cynarin (1, 5-di-O-caffeoylquinic acid) and chicoric acid (2, 3-O-dicaffeoyltartaric acid) and derivatives thereof; from about 0.2% to about 4% echinolone; from about 0.2% to about 8% echinacin B; from about 0.1% to about 6% echinaceine;  from about 2% to about 7% anthonocyanins comprising cynanidin 3-O-β-D-glucopyranoside and 3-O-(6-O-malonyl)-β-D glucopyranoside); from about 0.01% to about 0.06% pyrrolizidine alkaloids comprising tussilagine and isotussilagine; from about 0.003% to about 0.009% isomeric dodeca isobutyalamides and tetroenoic acid; and from about 0.01% to about 2% caryophylenes. 16. A method according to any of claims 11 to 15, characterized in that an Echinacea plant is selected from Echinacea purpurea and Echinacea angustifolia.